Biopharmas Escape 'Death Panel,' But 2017 Lurks
Executive Summary
Investors drove shares of biopharmaceutical companies up on June 22 on the news the projected growth rate in Medicare spending did not exceed the threshold needed this year to trigger the so-called Independent Payment Advisory Board (IPAB) to make recommendations for curbing spending. Republicans are opposed to the IPAB, calling it an "unelected and unaccountable board of bureaucrats," with some even dubbing it a "death panel."